CA2327450A1 - Maleate de paroxetine - Google Patents

Maleate de paroxetine Download PDF

Info

Publication number
CA2327450A1
CA2327450A1 CA002327450A CA2327450A CA2327450A1 CA 2327450 A1 CA2327450 A1 CA 2327450A1 CA 002327450 A CA002327450 A CA 002327450A CA 2327450 A CA2327450 A CA 2327450A CA 2327450 A1 CA2327450 A1 CA 2327450A1
Authority
CA
Canada
Prior art keywords
paroxetine
maleate
solution
toluene
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002327450A
Other languages
English (en)
Inventor
Victor Witold Jacewicz
David Alan Jones
John Man
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807627.6A external-priority patent/GB9807627D0/en
Priority claimed from GBGB9823856.1A external-priority patent/GB9823856D0/en
Application filed by Individual filed Critical Individual
Publication of CA2327450A1 publication Critical patent/CA2327450A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne le maléate de paroxétine et son obtention, ainsi que son utilisation pour le traitement et la prévention de la dépression notamment.
CA002327450A 1998-04-09 1999-04-09 Maleate de paroxetine Abandoned CA2327450A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9807627.6A GB9807627D0 (en) 1998-04-09 1998-04-09 Novel compounds
GB9807627.6 1998-04-09
GB9823856.1 1998-10-30
GBGB9823856.1A GB9823856D0 (en) 1998-10-30 1998-10-30 Novel compound
PCT/GB1999/001106 WO1999052901A1 (fr) 1998-04-09 1999-04-09 Maleate de paroxetine

Publications (1)

Publication Number Publication Date
CA2327450A1 true CA2327450A1 (fr) 1999-10-21

Family

ID=26313449

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002327450A Abandoned CA2327450A1 (fr) 1998-04-09 1999-04-09 Maleate de paroxetine

Country Status (18)

Country Link
EP (1) EP1073652A1 (fr)
JP (1) JP2002511466A (fr)
KR (1) KR20010042552A (fr)
CN (1) CN1305474A (fr)
AP (1) AP2000001950A0 (fr)
AU (1) AU3433499A (fr)
BG (1) BG104914A (fr)
BR (1) BR9909529A (fr)
CA (1) CA2327450A1 (fr)
EA (1) EA200001050A1 (fr)
HU (1) HUP0103651A3 (fr)
ID (1) ID26879A (fr)
IL (1) IL138920A0 (fr)
NO (1) NO20005037L (fr)
PL (1) PL343378A1 (fr)
SK (1) SK15032000A3 (fr)
TR (1) TR200002939T2 (fr)
WO (1) WO1999052901A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231833B1 (en) 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
GB9827387D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel process
GB9827431D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel compound
GB9914585D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
NL1017421C2 (nl) 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
ITTO20060143A1 (it) * 2006-02-28 2007-09-01 Bridgestone Corp Pneumatico

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
DE69704679T2 (de) * 1997-06-10 2001-09-13 Synthon Bv 4-phenylpiperidin-derivate

Also Published As

Publication number Publication date
IL138920A0 (en) 2001-11-25
AU3433499A (en) 1999-11-01
SK15032000A3 (sk) 2001-04-09
CN1305474A (zh) 2001-07-25
PL343378A1 (en) 2001-08-13
JP2002511466A (ja) 2002-04-16
HUP0103651A3 (en) 2002-12-28
WO1999052901A1 (fr) 1999-10-21
NO20005037L (no) 2000-12-05
AP2000001950A0 (en) 2000-12-31
EP1073652A1 (fr) 2001-02-07
BR9909529A (pt) 2000-12-12
EA200001050A1 (ru) 2001-04-23
ID26879A (id) 2001-02-15
TR200002939T2 (tr) 2001-02-21
NO20005037D0 (no) 2000-10-06
BG104914A (en) 2001-10-31
HUP0103651A2 (en) 2002-08-28
KR20010042552A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
US6063927A (en) Paroxetine derivatives
WO2003013529A1 (fr) Glycyrrhyzinate de paroxetine
CA2327450A1 (fr) Maleate de paroxetine
CA2319652A1 (fr) Sels de paroxetine
US20030028027A1 (en) Paroxetine maleate
CA2330055A1 (fr) Ascorbate de paroxetine
AU3618699A (en) Paroxetine 10-camphorsulfonate for treatment of cns disorders
MXPA00009884A (en) Paroxetine maleate
CZ20003722A3 (cs) Maleat paroxetinu
WO2000008016A1 (fr) Sels de paroxetine
AU724845B3 (en) Novel compound
MXPA00010435A (en) Paroxetine 10-camphorsulfonate for treatment of cns disorders
AU2528899A (en) Salts of paroxetine
MXPA00010439A (en) Paroxetine ascorbate
WO2001012623A1 (fr) Procede de preparation d'hydrochlorure de paroxetine anhydre
IES83541Y1 (en) Paroxetine methanesulfonate
MXPA00007719A (en) Salts of paroxetine
WO2000078752A1 (fr) Procede de production de chlorhydrate de paroxetine

Legal Events

Date Code Title Description
FZDE Discontinued